AKERO THERAPEUTICS INC. - COMMON STOCK

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023

10 Nov 2023 05:57:33 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

08 Nov 2023 04:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

17 Oct 2023 13:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

10 Oct 2023 04:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

09 Oct 2023 13:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology

04 Oct 2023 05:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at Upcoming Healthcare Conferences in September

31 Aug 2023 04:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023

28 Aug 2023 04:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

11 Aug 2023 03:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology

23 Jun 2023 04:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease

05 Jun 2023 04:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1

01 Jun 2023 13:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies Healthcare Conference

31 May 2023 05:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock

16 May 2023 15:53:36 By Nasdaq GlobeNewswire

Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

15 May 2023 04:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH

29 Mar 2023 13:01:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

17 Mar 2023 04:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

10 Jan 2023 05:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 05:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones

21 Dec 2022 13:01:00 By Nasdaq GlobeNewswire